ArticleBMJ open2026

Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.

Enrique Seco-Meseguer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.